StreetInsider.com News Articles

Anavex regains Nasdaq compliance after filing overdue reports

Wed, 02 Sep 2026 16:00:18 -0400

Anavex Life Sciences Corp. (NASDAQ: AVXL) announced it has received confirmation from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to file all required periodic reports with the Securities and Exchange Commission (SEC).

The company filed its outstanding Form 10-Q reports for the second and third fiscal quarters of 2026 with the SEC on August 28, 2026. With those filings submitted, Anavex is now in compliance with all Nasdaq listing standards, and its common stock will continue to trade on the Nasdaq Global Select Market under the ticker "AVXL."

Anavex is a clinical-stage biopharmaceutical company

Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement

Wed, 02 Sep 2026 16:00:00 -0400

Anavex Life Sciences is Pleased to Regain Full Compliance with Nasdaq, Continues to Execute on Clinical Development Strategy and Advance all Three Core Indications Forward

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs, today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires Nasdaq-listed companies to file all required periodic filings with

Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement

Wed, 02 Sep 2026 16:00:00 -0400

Anavex Life Sciences is Pleased to Regain Full Compliance with Nasdaq, Continues to Execute on Clinical Development Strategy and Advance all Three Core Indications Forward

Form 10-Q ANAVEX LIFE SCIENCES For: Jun 30

Fri, 28 Aug 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260828/26998453.html

Form 10-Q ANAVEX LIFE SCIENCES For: Jun 30

Fri, 28 Aug 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260828/26998453.html

Form 10-Q ANAVEX LIFE SCIENCES For: Mar 31

Fri, 28 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260828/26998410.html

Form 10-Q ANAVEX LIFE SCIENCES For: Mar 31

Fri, 28 Aug 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260828/26998410.html

Form 10-Q/A ANAVEX LIFE SCIENCES For: Dec 31

Fri, 28 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260828/26998383.html

Form 10-Q/A ANAVEX LIFE SCIENCES For: Dec 31

Fri, 28 Aug 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260828/26998383.html

Form 10-K/A ANAVEX LIFE SCIENCES For: Sep 30

Fri, 28 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260828/26998357.html

Form 10-K/A ANAVEX LIFE SCIENCES For: Sep 30

Fri, 28 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260828/26998357.html

Form DEFC14A ANAVEX LIFE SCIENCES Filed by: PVG ASSET MANAGEMENT CORP

Thu, 27 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260827/26991259.html

Form DEFC14A ANAVEX LIFE SCIENCES Filed by: PVG ASSET MANAGEMENT CORP

Thu, 27 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260827/26991259.html

Form PRRN14A ANAVEX LIFE SCIENCES Filed by: PVG ASSET MANAGEMENT CORP

Thu, 27 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260827/26984080.html

Form PRRN14A ANAVEX LIFE SCIENCES Filed by: PVG ASSET MANAGEMENT CORP

Thu, 27 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260827/26984080.html

Form 8-K ANAVEX LIFE SCIENCES For: Aug 25

Tue, 25 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260825/26971363.html

Form 8-K ANAVEX LIFE SCIENCES For: Aug 25

Tue, 25 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260825/26971363.html

Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update

Tue, 25 Aug 2026 08:00:00 -0400

Clinical Development Strategy for Alzheimer’s Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs

Anavex Submits Completed Alzheimer’s Disease Clinical Study Data and Rett Syndrome Formal Meeting Request to FDA, with an IND Submission for Fragile X Syndrome Planned for September

NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs, today reported a business update and financial results for its third

Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update

Tue, 25 Aug 2026 08:00:00 -0400

Clinical Development Strategy for Alzheimer’s Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs

Anavex Submits Completed Alzheimer’s Disease Clinical Study Data and Rett Syndrome Formal Meeting Request to FDA, with an IND Submission for Fragile X Syndrome Planned for September

Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update

Tue, 25 Aug 2026 08:00:00 -0400

Clinical Development Strategy for Alzheimer’s Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs

Anavex Submits Completed Alzheimer’s Disease Clinical Study Data and Rett Syndrome Formal Meeting Request to FDA, with an IND Submission for Fragile X Syndrome Planned for September

Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update

Tue, 25 Aug 2026 08:00:00 -0400

Clinical Development Strategy for Alzheimer’s Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs

Anavex Submits Completed Alzheimer’s Disease Clinical Study Data and Rett Syndrome Formal Meeting Request to FDA, with an IND Submission for Fragile X Syndrome Planned for September

Form DEFA14A ANAVEX LIFE SCIENCES

Mon, 24 Aug 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260824/26964458.html

Form DEFA14A ANAVEX LIFE SCIENCES

Mon, 24 Aug 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260824/26964458.html

Form DFAN14A ANAVEX LIFE SCIENCES Filed by: PVG ASSET MANAGEMENT CORP

Thu, 20 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260820/26952190.html

Form DFAN14A ANAVEX LIFE SCIENCES Filed by: PVG ASSET MANAGEMENT CORP

Thu, 20 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260820/26952190.html